Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Tag: CTD
Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Cyclo Therapeutics, Inc. formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, announced
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Announces Partnership with United BioSource
CTD Holdings, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,